Papers

1

Total Citations

10

H-Index

1

About

Dr. Sandro Pignata is a leading figure in urologic oncology, with a specialized focus on the surgical management of testicular cancer, particularly non-seminomatous germ cell tumors (NSGCT). His major contributions center on refining post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND), a critical but morbid procedure. Through his work, including a highly cited 2023 study on unilateral robot-assisted PC-RPLND, Dr. Pignata has championed the adoption of modified surgical templates and minimally invasive techniques to reduce morbidity while maintaining oncologic efficacy. His research demonstrates that robotic approaches can achieve excellent outcomes in select Stage II NSGCT patients, advancing the field toward more personalized, less invasive care. With over 10 citations on this key paper alone, his work is shaping contemporary surgical standards. Dr. Pignata’s dedication to improving recovery and quality of life for young men facing testicular cancer marks him as an innovator in urologic surgery, bridging the gap between aggressive cancer control and functional preservation.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor: A tertiary care experience
10 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago